SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-005890
Filing Date
2020-01-13
Accepted
2020-01-13 07:12:09
Documents
14
Period of Report
2020-01-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d760527d8k.htm   iXBRL 8-K 28214
2 EX-99.1 d760527dex991.htm EX-99.1 31696
6 GRAPHIC g760527g0110075450793.jpg GRAPHIC 3606
  Complete submission text file 0001193125-20-005890.txt   198295

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20200113.xsd EX-101.SCH 3076
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20200113_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20200113_pre.xml EX-101.PRE 11412
9 EXTRACTED XBRL INSTANCE DOCUMENT d760527d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 20522747
SIC: 2834 Pharmaceutical Preparations